livemint.com
38%
278
Novavax covid-19 vaccine shows 90% efficacy in US phase 3 trial
vaccine had an efficacy of 90%.The vaccine is also being contract manufactured in India under the brand Covovax by Serum Institute of India, which is also currently conducting a local bridging study here."Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines," Novavax president and chief executive officer Stanley C. Erck said in a statement on Monday.The phase 3 trial in the US and Mexico showed that the vaccine had an overall efficacy of 90.4% in a group of 29,960 participants across 119 sites in the country.